Arkolith/Insider Trading/MNPR/Form 4

Robinson Chandler

Chief Executive Officer, DirectorMonopar Therapeutics (MNPR) · full profile →Form 4 · filed Mar 7, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2025Option exercise(M)6K——65K
Mar 4, 2025Tax withholding(F)2K$31.70$56K63K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 4, 2025Grant(A)80K—$0105K
Mar 4, 2025Option exercise(M)6K—$099K
Mar 4, 2025Grant(A)86K—$086K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-25-006736) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML